(Q38048818)

27 August 2017

Decision-making tools to assist prognosis and treatment choices in early breast cancer: a review (English)

1 reference

27 August 2017

1 reference

Asmaa Al-Allak

1

1 reference

27 August 2017

Paul D Lewis

series ordinal

2

1 reference

27 August 2017

Gianfilippo Bertelli

series ordinal

3

1 reference

27 August 2017

language of work or name

1 reference

1 August 2012

1 reference

Expert Review of Anticancer Therapy

27 August 2017

1 reference

27 August 2017

12

1 reference

27 August 2017

8

1 reference

27 August 2017

1033-1043

1 reference

Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database

27 August 2017

1 reference

Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare

21 January 2018

1 reference

History of aromatase: saga of an important biological mediator and therapeutic target

21 January 2018

1 reference

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

21 January 2018

1 reference

Breast-cancer adjuvant therapy with zoledronic acid

21 January 2018

1 reference

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.

21 January 2018

1 reference

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

21 January 2018

1 reference

Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.

21 January 2018

1 reference

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

21 January 2018

1 reference

Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.

21 January 2018

1 reference

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

21 January 2018

1 reference

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer

21 January 2018

1 reference

Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.

21 January 2018

1 reference

Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.

21 January 2018

1 reference

A prognostic index in primary breast cancer

21 January 2018

1 reference

Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?

21 January 2018

1 reference

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

Population-based validation of the prognostic model ADJUVANT! for early breast cancer

21 January 2018

1 reference

Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model

21 January 2018

1 reference

Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer

21 January 2018

1 reference

Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.

21 January 2018

1 reference

Adjuvant! Online is overoptimistic in predicting survival of Asian breast cancer patients.

21 January 2018

1 reference

PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer

21 January 2018

1 reference

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

21 January 2018

1 reference

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

21 January 2018

1 reference

The influence of a gene expression profile on breast cancer decisions

21 January 2018

1 reference

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.

21 January 2018

1 reference

Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer

21 January 2018

1 reference

Histopathologic variables predict Oncotype DX recurrence score

21 January 2018

1 reference

Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer.

21 January 2018

1 reference

Ki67 in breast cancer: prognostic and predictive potential

21 January 2018

1 reference

Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients

21 January 2018

1 reference

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

21 January 2018

1 reference

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice.

21 January 2018

1 reference

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

21 January 2018

1 reference

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis

21 January 2018

1 reference

Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma

21 January 2018

1 reference

Molecular portraits of human breast tumours

21 January 2018

1 reference

Supervised risk predictor of breast cancer based on intrinsic subtypes

21 January 2018

1 reference

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer

21 January 2018

1 reference

Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.

21 January 2018

1 reference

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

21 January 2018

1 reference

An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom

21 January 2018

1 reference

Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US

21 January 2018

1 reference

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

21 January 2018

1 reference

Triple-negative breast cancer: therapeutic options

21 January 2018

1 reference

St. Gallen 2011: Summary of the Consensus Discussion

21 January 2018

1 reference

Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.12.83

1 reference

27 August 2017

1 reference